NetScientific announces investment in DName-iT bringing important improvements to diagnostic Next Generation Sequencing

11:51 EST 7 Jan 2015 | Instinctif Partners

7 January 2015 - NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced its investment in DName-iT NV (“DName-iT”) a spin-out from KU Leuven in Belgium

As a subsidiary company of NetScientific, DName-iT is developing a “solution of choice” for improving the quality and workflow of genetic diagnostic tests based on next generation sequencing (“NGS”).

Current genetic tests are complex and involve many steps which are prone to errors. Diagnosis errors do occur and are important, but represent an underemphasised and understudied area of patient safety. Diagnosis errors are challenging to detect and it is even harder to determine with certainty their cause and consequence.

DName-iT’s core products will include the DName molecules, accessory consumables and software for use in NGS. They will allow absolute quality control and automation of a broad range of tests in different fields in genetic labs.

Farad Azima, CEO of NetScientific, said: “Patients are receiving erroneous results from genetic tests. DName-iT has a potentially transformative technology that will help reduce such errors. For NetScientific, this investment secures an additional offering in our genomic-space personalised medicine portfolio.”

Paul van Dun, General Manager of KU Leuven R&D, added: “When talking to potential partners for the further development of our technologies, we were impressed by the vision and network of NetScientific. We believe the collaboration with NetScientific creates an optimal setting for turning the technologies into products and services that will benefit society.

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at MailScanner has detected a possible fraud attempt from "" claiming to be
About KU Leuven

Katholieke Universiteit Leuven, founded in 1425, is one of the oldest universities in Europe and is a world-leader in life sciences.  The research intensive university combines values of high quality innovation with exceptional facilities, which include a network of teaching hospitals.  The university has a successful track record in licensing various technologies and novel drug molecules to major companies around the world.

NetScientific plc Farad Azima Liberum (NOMAD and Broker) Chris Bowman / Christopher Britton Instinctif Partners Melanie Toyne-Sewell / Tim Watson Tel: +44 (0) 207 313 9777 Tel: +44 (0) 20 3100 2000 Tel: +44 (0) 20 7457 2020 Email: NEXT ARTICLE

More From BioPortfolio on "NetScientific announces investment in DName-iT bringing important improvements to diagnostic Next Generation Sequencing"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...